MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z
  • Hand skin temperature and its response to cooling in clinical differentiation of multiple system atrophy and Parkinson’s disease

    S. Augustis, T. Fiesel, W.H. Jost (Kaunas, Lithuania)

  • Handwriting in Parkinson′s disease: Systematic review and preliminary study

    C. Simonet, A.J. Noyce, H. Ling, A.J. Lees, T.T. Warner (Segovia, Spain)

  • Has iCare PD started in Singapore?

    S.H.X. Liew, C. Cyq, N. Jcf, K. Sym, R.C.L. Ong (Singapore, Singapore)

  • Head and trunk control during stair ascent and descent in people with Parkinson’s disease

    Z.J. Conway, P.A. Silburn, T.D. Blackmore, M.H. Cole (Brisbane, Australia)

  • Head drop in patient with Parkinson’s disease as an alert of upcoming myasthenic chrisis

    V. Vuletic (Zagreb, Croatia)

  • Headache in patients with Parkinsons disease: Pilot study results

    V. Aldinio, N.S. Araoz Olivos, R. Maiola, F.E. Micheli (Buenos Aires, Argentina)

  • Health related quality of life in patient with Parkinson’s disease using deep brain stimulators (DBS)- A cross sectional study

    F. Pullishery, A. Abraham (Malappuram, India)

  • Health-related quality of life of multisystem atrophy and progressive supranuclear palsy patients

    M. Figura, L. Milanowski, B. Kierdaszuk, A. Bartoszek, P. Janik, Z. Jamrozik (Warsaw, Poland)

  • Healthcare burden of Parkinson’s disease

    M. Tagliati, A.T. Connolly (Los Angeles, CA, USA)

  • Heart rate variability and sympathetic skin response are useful in the evaluation of Parkinson’s disease, AMS, and Parkinson plus syndrome, but underutilized in daily clinical practice

    R.C. Callejas Rojas, B. Estañol Vidal (Mexico, Mexico)

  • Heart rate variability to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment

    J. Yoon, S.M. Lee, J.M. Hong (Suwon, Korea)

  • Hemi-stereotypies symptomatic to aneurysm: Differential diagnosis of tardive dyskinesia

    D. Rebolledo, P.O. Gonzalez, Z. Rebolledo, A.G.S. Fokine Dotsenko (La Magdalena, Toluca de Lerdo, Mexico)

  • Hemifacial spasm – Therapeutic assessment of botulinum toxin

    H.A.G. Teive, J.P. Matisti, A.D. Kleinfelder, N.B. Galli (Curitiba, Brazil)

  • Hemifacial spasm: Objective computation of vertebrobasilar vascular sinuosity

    L. Chan, E.C. Edmond, S.X.L. Sim, H. Li, E. Tan (Singapore, Singapore)

  • Hereditary atypical parkinsonism with novel mutation of the VPS35 and FBXO7 genes

    K. Mensikova, T. Bartonikova, L. Mikulicova, R. Vodicka, R. Vrtel, M. Godava, I. Dolinova, M. Vastik, M. Kaiserova, P. Otruba, P. Kanovsky (Olomouc, Czech Republic)

  • Hereditary spastic paraplegia caused by heterozygous AFG3L2 and SPG7 mutations

    C.D. Stephen, J.D. Schmahmann (Boston, MA, USA)

  • Heterozygous TUBB4A knock-out impairs mitochondrial motility in human neuronal model of DYT4

    V. Krajka, F. Vulinovic, P. Seibler, K. Lohmann, C. Klein, A. Rakovic (Luebeck, Germany)

  • Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

    W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

  • High frequency of mutations in the glucocerebrosidase (GBA) gene among Ashkenazi Jews with dementia with Lewy bodies

    T. Shiner, A. Mirelman, M. Gana Weisz, A. Bar-Shira, E. Ash, R. Cialic, T. Gurevich, N. Bregman, A. Orr-Urtreger, N. Giladi (Tel Aviv, Israel)

  • High throughput pooled-DNA sequencing of mendelian/susceptibility Parkinson’s disease genes in Spanish population

    S. Ortega-Cubero, O. Lorenzo-Betancor, E. Lorenzo, B.A. Benitez, C. Cruchaga, L. Samaranch, M. Diez, J.A. Obeso, M.C. Rodriguez-Oroz, M. Aguilar, M.A. Pastor, P. Pastor (Palencia, Spain)

  • High voltage stimulation of the VIM thalamus mimicking PSP in a patient with ET + PD

    A.K. Patterson, L. Shahgholi, C.W. Hess (Gainesville, FL, USA)

  • Higher doses of dopamine agonists, impulse control disorders and history of deep brain stimulation (DBS): Risk factors for dopamine agonists withdrawal syndrome (DAWS)?

    X. Garcia, S. Patel, M.E. Mohammad, X.X. Yu, K. Sutton, K. O'Donnell, H. Fernandez (Cleveland, OH, USA)

  • Highlighting the spectrum of practice in the routine management of cervical dystonia with botulinum neurotoxin-A: Baseline injection practice data from MetaCD

    R. Trosch, V.P. Misra, S. Om, P. Maisonobe (Farmington Hills, MI, USA)

  • Histochemical evaluation of the effect of vitamin E on cyanide–induced damage on the prefrontal cortex of Sprague Dawley rats

    A.O. Adekeye, P.D. Shallie (Ado-Ekiti, Nigeria)

  • Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature

    R.W.K. Borgemeester, G.F.H. Diercks, M.L.A. Schuttelaar, T. van Laar (Groningen, Netherlands)

  • Histone deacetylase 4 is regulated by microRNA 128 in SH-SY5Y cells of Parkinson’s disease

    J. Li, N. Xiong, H. Jiang, L. Liu, C. Han, K. Ma, X. Xu, Y. Shen, Y. Xia, L. Wang, S. Guo, J. Huang, T. Wang (Wuhan, People's Republic of China)

  • Home care program for patients with Parkinson’s disease – A Singapore experience

    H.L. Ng, W. Li, S. Abdul Karim, K.Y. Tay, W.L. Au, L.C.S. Tan (Singapore, Singapore)

  • Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

    S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

  • How accurate is the prediction of driving ability in a Parkinson’s clinic setting?

    C. Thomas, R. Amin, B. Mohamed (Cardiff, United Kingdom)

  • How do cognitive profiles differ in patients with Parkinson’s disease with cognitive decline in comparison to patients remaining cognitively stable? Preliminary results of a 3 years follow-up study

    A. Meyer, U. Gschwandtner, V. Cozac, F. Hatz, P. Fuhr (Basel, Switzerland)

  • How do patients experience deep brain stimulation surgery: A prospective patient satisfaction survey

    A. Fazl, M. Gillego, A. Mogliner, M.H. Pourfar (New York, NY, USA)

  • How do we clinically distinguish subtypes of myoclonus? A retrospective study

    R. Zutt, J.W. Elting, H. van der Hoeven, F. Lange, M.A.J. Tijssen (Groningen, Netherlands)

  • How do we make mistakes diagnosing movement disorders?

    J. Rosales, N. Larripa, C.A. Del Carpio, S.A. Rodríguez-Quiroga, L. Assante, J. Cassen, T. Arakaki, N.S. Garretto (Caba, Argentina)

  • How does cognition affect reaching in Parkinson’s disease?

    J. Cosgrove, C. Picardi, S.L. Smith, S. Jamieson, J.E. Alty (Leeds, United Kingdom)

  • How does preprocessing affect estimation of causal information transfer in the human brain?

    I. Weber, E. Florin, F. Jung, M. von Papen, L. Timmermann (Cologne, Germany)

  • How long is the wait to see a Parkinson’s disease specialist in the United States?

    S.G. Reich, K. Holmes, J. Martello, K. Maki (Baltimore, MD, USA)

  • How many and which kind of Parkinson’s disease patients need deep brain stimulation surgery? An evaluation based on clinical observation of patients with disease history of 15th year or more

    H. Shibayama, T. Fukumoto, M. Tomura, K. Tokumoto, H. Yano, K. Tajima, F. Mitobe, F. Katada, S. Sato, T. Fukutake (Kamogawa City, Chiba, Japan)

  • How satisfied are cervical dystonia patients with their botulinum toxin treatment? Findings from an international observational study

    V.P. Misra, C. Colosimo, D. Charles, T.M. Chung, P. Maisonobe, S. Om (London, United Kingdom)

  • Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo

    A. Weihofen, H. Patel, C. Huy, C. Liu, I. Combaluzier, S. Mueller-Steiner, N. Cavegn, L. Strobel, T.M. Engber, K.J. Rhodes, C. Hock, R.M. Nitsch, F. Montrasio, J. Grimm, A. Dunah, P.H. Weinreb (Cambridge, MA, USA)

  • Human, fly and cellular models of riboflavin transporter neuronopathy

    A. Manole, A. Pandraud, M.M. Reilly, J.E.C. Jepson, H. Houlden (London, United Kingdom)

  • Huntington disease phenocopies or misdiagnosis: A black South African cohort

    F.K. Baine, A. Krause (Johannesburg, South Africa)

  • Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease

    L. Zhang, M. Wang, J. Zhu, Y. Pan, J. Dong (Nanjing, People's Republic of China)

  • Hyperekplexia secondary to cumulative novel glycine pathway mutations

    S. Nandipati, S. Ceulemans, J. Friedman (La Jolla, CA, USA)

  • Hyperin inhibits lipopolysaccharide-induced microglia activation through p38 and NFκB signaling

    X. Zhang, Y.N. Wang, H.H. Fan, R. Yang, S.Y. Li, J.H. Zhu (Wenzhou, People's Republic of China)

  • Hyposmia as a predictor of non-motor symptom in patients with de novo Parkinson’s disease

    M. Sanoeva, N. Mansurova, A. Prokhorova (Bukhara, Uzbekistan)

  • Hypothalamic alpha-synuclein pathology and its relation to non-motor symptoms and disease progression in Parkinson’s disease

    E. De Pablo-Fernandez, R. Courtney, J.L. Holton, T.W. Warner (London, United Kingdom)

  • Hypothalamic volume loss is associated with reduced melatonin output in Parkinson’s disease

    D.P. Breen, C. Nombela, R. Vuono, P.S. Jones, K. Fisher, D.J. Burn, D.J. Brooks, A.B. Reddy, J.B. Rowe, R.A. Barker (Cambridge, United Kingdom)

Jump to:  View All • a b c d e f g [h] i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley